Business
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0955 ET – The American Society of Clinical Oncology published an abstract of a study that JPMorgan calls “highly encouraging” for the targeted chemotherapy sac-TMT treatment jointly developed by Merck and Chinese biotech firm Kelun-Biotech. “Sac-TMT reduced the risk of death or progression on the combined population by 65%,” the analysts say. However, they also say in the note that the drug was compared to Merck’s own Keytruda monotherapy, which is not the standard of care in most parts of the world, making drawing comparisons difficult. “The data is nonetheless solid…and continues to derisk sac-TMT,” the analysts say. Merck is up 4%.(nicholas.miller@wsj.com)
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
You must be logged in to post a comment Login